Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
Elutia to Present at the 16th Annual LD Micro Invitational May 18th
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Elutia Regains Compliance with Nasdaq Listing Requirements
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Elutia (NASDAQ:ELUT) Shares Up 4.7% – Should You Buy?
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
Elutia (NASDAQ:ELUT) Director Purchases $26,000.00 in Stock
Elutia (NASDAQ:ELUT) Stock Price Down 0.9% – What’s Next?
Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
Down 25.9% in 4 Weeks, Here's Why ELUTIA INC (ELUT) Looks Ripe for a Turnaround
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
All You Need to Know About ELUTIA INC (ELUT) Rating Upgrade to Buy
Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award
New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices
Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
Elutia Confirms No Material Impact from Global Tariffs
Elutia to Participate in Upcoming Investor Conferences
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™